<DOC>
	<DOCNO>NCT02020720</DOCNO>
	<brief_summary>This pilot clinical trial study fluorine F 18 fluorodopa ( 18F-DOPA ) -positron emission tomography ( PET ) planning surgery patient gliomas . New image procedure , 18F-DOPA-PET scan , may help find glioma may help planning surgery .</brief_summary>
	<brief_title>18F-DOPA-PET Planning Surgery Patients With Gliomas</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Accurately define standardize 18F-DOPA PET tumor/normal tissue ( T/N ) threshold delineate high grade glioma ( HGG ) low grade glioma ( LGG ) . SECONDARY OBJECTIVES : I . Determine correlation 18F-DOPA PET activity , magnetic resonance imaging ( MRI ) contrast enhancement high- low-grade glioma biopsy . II . Compare grade maximum 18F-DOPA uptake sample resection patient final diagnostic grade , base high grade component stereotactic non-stereotactic sample acquire open resection patient . III . Compare volume difference 18F-DOPA PET activity , MRI contrast enhancement , perfusion MRI ( pMRI ) , diffusion tensor imaging ( DTI ) neurosurgical planning . IV . Assess time progression patient receive resection biopsy . TERTIARY OBJECTIVES : I . Compare histopathology correlation 18F-DOPA PET correlation perfusion MR image accurate identification high grade/highest density disease . II . Compare histopathology correlation 18F-DOPA PET correlation diffusion tensor image information accurate identification tumor extent . III . Compare neurosurgical resection extent volume delineation without 18F-FDOPA-PET metabolic image information determine role metabolic image neurosurgical resection planning . OUTLINE : Within 1 week biopsy resection , patient undergo 18F-DOPA PET/computed tomography ( CT ) scan pMRI DTI baseline . Patients undergo stereotactic craniotomy image-guided biopsy . After completion study treatment , patient follow yearly 5 year .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Dihydroxyphenylalanine</mesh_term>
	<criteria>MRI finding compatible newly diagnose recurrent high lowgrade malignant glioma Planned craniotomy resection biopsy Willing sign release information radiation and/or followup record Provide inform write consent &gt; = 18 year ; &lt; 18 year , provide inform write assent parent legal guardian provide inform write consent Ability provide tissue mandatory correlative research component Unable undergo MRI scan contrast ( e.g . cardiac pacemaker , defibrillator , kidney failure ) Unable undergo 18FDOPA PET scan ( e.g . Parkinson 's disease , take antidopaminergic , dopamine agonist medication le 6 halflives discontinuance dopamine agonist ; NOTE : potentially interfere drug : amoxapine , amphetamine , benztropine , buproprion , buspirone , cocaine , mazindol , methamphetamine , methylphenidate , norephedrine , phentermine , phenylpropanolamine , selegiline , paroxetine , citalopram , sertraline ; patient drug , list one onstudy form Any following : Pregnant woman Nursing woman Men woman childbearing potential unwilling employ adequate contraception</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>